Advertisement

NLS Diamyd

Careers article - October 12, 2020

Recruitment drive underway at Diamyd Medical

The company is moving its production of the GAD65 protein, the active substance in its diabetes vaccine Diamyd, from abroad to Umeå, Sweden. The new unit is around 1,000 square meters in size and contains clean rooms, laboratories and offices. Today, the unit has six employees, including protein scientists and quality management. ”We are short […]

Clinical Trials - April 4, 2016

Diamyd’s study approved for expansion

Diamyd Medical today announced that DIAGNODE-1, an open-label clinical pilot study in which the diabetes vaccine Diamyd is administered directly into lymph nodes, has been approved by the Swedish Medical Products Agency and the Ethics Review Board to be expanded from five to nine patients and to include children from 12 years of age. Professor […]

MedTech Business - February 29, 2016

Diamyd Medical’s rights issue oversubscribed

Diamyd Medical has completed a new share issue with preferential rights for existing shareholders through which the company will receive proceeds of MSEK 22.1 before issue expenses. There has been substantial interest in the issue. Subscription applications totaling approximately MSEK 45.8 were received, corresponding to a subscription rate of about 207 percent. 94.6 percent of the […]

Clinical Trials - February 20, 2016

Preliminary interim report from Diamyd’s DIAGNODE-1

Diamyd Medical announces that the first six-month interim report from DIAGNODE-1, a clinical pilot study in which the diabetes vaccine Diamyd is administered directly into lymph nodes, preliminarily shows that the treatment appears to be safe and tolerable and that the clinical progression in patients is positive in terms of the body’s own capacity to […]

Uncategorized - August 1, 2015

Cellaviva launches new service

Diamyd Medical’s associated company Cellaviva launches service for private family saving of stem cells. Diamyd Medical has announced that the their associated company Cellaviva AB on September 1 launches its service in which expecting parents in Sweden can save stem cells from their newborn child. Stem cells from the baby’s umbilical cord are saved and stored […]

Collaboration - May 11, 2015

Biobank Could Help Diamyd with Diabetes Vaccine

Diamyd, which is developing a vaccine against type 1 diabetes, now owns 39 percent of Cellaviva, Sweden’s first commercial biobank for stem cells. Diamyd made the investment because of the potential resource for research. “We believe in stem cells. Among other things, we hope that in the future we will be able to use them […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.